OncoMatch/Clinical Trials/NCT07029399
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Is NCT07029399 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies NKT5097 CDK2/CDK4 dual degrader for hr+ breast cancer.
Treatment: NKT5097 CDK2/CDK4 dual degrader — The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2 * What medical issues/symptoms do participants experience when taking NKT5097
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Tumor Agnostic
Ovarian Cancer
Endometrial Cancer
Biomarker criteria
Required: CCNE1 amplification
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Adequate organ function
Kidney function
Adequate organ function
Liver function
Adequate organ function; Significant liver disease (Child Pugh class B or C) [excluded]
Adequate organ function; Significant liver disease (Child Pugh class B or C) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Yale Cancer Center · New Haven, Connecticut
- SCRI Florida Cancer Specialists - Sarasota · Sarasota, Florida
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify